CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) — Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced today today that members of management will participate in the Virtual Investor Management and KOL Roundtable Event on Tuesday, May 3, 2022 at 10:00 a.m. ET.
Attending Palisade Bio’s leadership team will be Tom Hallam, Ph.D., Chief Executive Officer, Michael Dawson, MD, Chief Medical Officer and Robert McRae, Senior Vice President, Operations and Strategic Development.
Palisade Bio’s leadership will be joined by key thought leader, David B. Hoyt, MD, FACS, MAMSE. Dr. Hoyt is Executive Director of the American College of Surgeons (ACS), a founding member of the ACS Academy of Master Surgeon Educators™, a member of the ACS Steering Committee for the Academy, and Emeritus Professor of Surgery at the University of California, Irvin.
As part of the virtual event, Palisade Bio will discuss the importance of gut barrier health and how it is developing targeted therapies to protect and repair the integrity of the gastrointestinal tract. In addition to the moderated portion of the event, investors and interested parties will have the opportunity to submit questions. The Company will answer as many questions as possible during the event.
A live video webcast of the Virtual Investor Roundtable will be available in the Latest Events and Presentations section of the Investors page of Palisade Bio’s website (palisadebio.com). A webcast will be available two hours after the live presentation and will be accessible for 90 days.
About LB1148
LB1148 is a new oral liquid formulation of the well-characterized digestive enzyme inhibitor, tranexamic acid (“TXA”), with the potential to both reduce abdominal adhesions and help restore bowel function after a surgical intervention. The therapy is being developed for administration prior to major surgeries that risk disrupting the intestinal epithelial barrier. Evidence suggests that the release of digestive proteases contributes to the temporary loss of normal gastrointestinal function and the formation of postoperative adhesions. By inhibiting the activity of these digestive proteases, LB1148 has the potential to prevent gastrointestinal tissue damage, accelerate the time to return to normal gastrointestinal function, and shorten the length of costly post-operative hospital stays. .
The US FDA has granted Fast Track Designation to LB1148 for two clinical indications: the reduction of adhesions after abdominal or pelvic surgery and the treatment of postoperative gastrointestinal dysfunction in pediatric patients undergoing cardiac surgery.
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company advancing therapies that help patients with acute and chronic gastrointestinal complications resulting from postoperative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, which is progressing to Phase 3, is a protease inhibitor with the potential to reduce abdominal adhesions and help restore bowel function after surgery. Positive Phase 2 trial data of LB1148 demonstrated safety and tolerability as well as statistically significant improvement in return of bowel function and decreased length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad of health issues and complications associated with chronic disruption of the gastrointestinal epithelial barrier. For more information, visit www.palissadebio.com.
Forward-looking statements
This communication contains “forward-looking” statements, including, without limitation, statements relating to expectations regarding Palisade’s plans for future presentations at investor conferences. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based on Palisade’s current expectations. Forward-looking statements involve risks and uncertainties. Palisade’s actual results and timing of events could differ materially from those anticipated in these forward-looking statements due to such risks and uncertainties, which include, but are not limited to, the Company’s ability to advance its clinical programs and the uncertain and time consuming regulatory approval process. Additional risks and uncertainties can be found in Palisade Bio’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Palisade expressly disclaims any obligation or undertaking to publicly release any updates or revisions to the forward-looking statements contained herein to reflect any change in Palisade’s expectations with respect thereto or any change in events, conditions or circumstances on which such statements are based..
Organic Palisade Contact
Dawn Hofmeister
[email protected]
Investor Relations
JTC Team, LLC
jenene thomas
833-475-8247
[email protected]
